Search

Galaxies usually follow a mass–metallicity relation, where higher mass galaxies are typically more metal-rich than lower mass galaxies. Yet, tidal dwarf galaxies are outliers to this relation. These kinds of dwarfs are formed in galactic mergers. Since their material comes from the parent galaxies, they are typically more metal-rich than regular dwarfs. However, galaxies were far less enriched when the Universe was younger. One can ask if tidal dwarfs that formed at high redshift could be chemically distinguished from regular dwarfs. To answer this question, we performed a series of numerical simulations of gas-rich galaxy mergers at high redshift. We then identified the dwarf galaxies that formed in these mergers, and studied the evolution of their metal content. While the initial abundance of metals in the progenitors was low, the merger allows rapid enrichment and all tidal dwarf galaxies end up with high abundances. Their mass–metallicity relation is well fitted by the relation $12+\log ({\rm O/H})=5.47+0.415\log (M_*/\,{\rm {M}_\odot})$, putting them well above the observed relation for local dwarfs galaxies. We conclude that tidal dwarfs should be outliers to the mass–metallicity relation, no matter the epoch of formation.

Through the efficient clearance of extracellular glutamate, high affinity astrocytic glutamate transporters constantly shape excitatory neurotransmission in terms of duration and spreading. Even though the glutamate transporter GLT-1 (also known as EAAT2/SLC1A2) is amongst the most abundant proteins in the mammalian brain, its density and activity are tightly regulated. In order to study the influence of changes in the expression of GLT-1 on glutamate uptake capacity, we have developed a model in HEK cells where the density of the transporter can be manipulated thanks to a tetracycline-inducible promoter. Exposing the cells to doxycycline concentration-dependently increased GLT-1 expression and substrate uptake velocity. However, beyond a certain level of induction, increasing the density of transporters at the cell surface failed to increase the maximal uptake. This suggested the progressive generation of a pool of spare transporters, a hypothesis that was further validated using the selective GLT-1 blocker WAY-213613 of which potency was influenced by the density of the transporters. The curve showing inhibition of uptake by increasing concentrations of WAY-213613 was indeed progressively rightward shifted when tested in cells where the transporter density was robustly induced. As largely documented in the context of cell-surface receptors, the existence of 'spare' glutamate transporters in the nervous tissue and particularly in astrocytes could impact on the consequences of physiological or pathological regulation of these transporters.

Les personnes atteintes de troubles mentaux graves sont placées quotidiennement devant des difficultés qui nuisent à leur participation et intégration sociales. Elles sont également plus à risque d’être sans emploi et de vivre une situation socioéconomique difficile. Ces obstacles les placent particulièrement à risque de vivre de l’insécurité alimentaire. Cuisinons Ensemble est une initiative communautaire orientée vers le rétablissement qui permet de soutenir les personnes dans le développement de compétences alimentaires et dans leur intégration sociale. Cet article propose de présenter le modèle de Cuisinons Ensemble ainsi que les enjeux de sa mise en place., The challenges people with severe mental health disorders face in their daily lives impede their social participation and integration. They are facing higher risk of unemployment and are more likely to have a low socio-economic status. These obstacles put them greatly at risk of experiencing food insecurity. Cuisinons Ensemble is a community initiative based on a recovery-oriented approach that supports the development of food skills and the social integration of people living with a mental health disorder. This article presents the Cuisinons Ensemble initiative model and the issues related to its implementation.

Vasoactive intestinal peptide (VIP) has potent immune modulatory actions that may influence the course of neurodegenerative disorders associated with chronic inflammation. Here, we show the therapeutic benefits of a modified peptide agonist stearyl-norleucine-VIP (SNV) in a transgenic rat model of amyotrophic lateral sclerosis (mutated superoxide dismutase 1, hSOD1(G93A)). When administered by systemic every-other-day intraperitoneal injections during a period of 80 days before disease, SNV delayed the onset of motor dysfunction by no less than three weeks, while survival was extended by nearly two months. SNV-treated rats showed reduced astro- and microgliosis in the lumbar ventral spinal cord and a significant degree of motor neuron preservation. Throughout the treatment, SNV promoted the expression of the anti-inflammatory cytokine interleukin-10 as well as neurotrophic factors commonly considered as beneficial in amyotrophic lateral sclerosis management (glial derived neuroptrophic factor, insulin like growth factor, brain derived neurotrophic factor). The peptide nearly totally suppressed the expression of tumor necrosis factor-α and repressed the production of the pro-inflammatory mediators interleukin-1β, nitric oxide and of the transcription factor nuclear factor kappa B. Inhibition of tumor necrosis factor-α likely accounted for the observed down-regulation of nuclear factor kappa B that modulates the transcription of genes specifically involved in amyotrophic lateral sclerosis (sod1 and the glutamate transporter slc1a2). In line with this, levels of human superoxide dismutase 1 mRNA and protein were decreased by SNV treatment, while the expression and activity of the glutamate transporter-1 was promoted. Considering the large diversity of influences of this peptide on both clinical features of the disease and associated biochemical markers, we propose that SNV or related peptides may constitute promising candidates for amyotrophic lateral sclerosis treatment.

Altered expression and activity of GLT-1 have been characterized in amyotrophic lateral sclerosis (ALS) patients and in animal models of the disease. Data suggest that the expression of two C-terminus splice variants of GLT-1 (namely GLT-1a and GLT-1b) can be differentially regulated in this pathological context. We herein characterized the expression of GLT-1a and GLT-1b mRNA and the glutamate uptake activity in the fronto-temporal cortex and the lumbar spinal cord of transgenic rats expressing hSOD1G93A at various stages of the disease. We also investigated the expression and activity of the other key glutamate transporters GLAST and EAAC1. While the progression of the disease was associated with a reduction of the overall GLT-1 activity in both cortex and spinal cord, the regulation of GLT-1a and GLT-1b transcripts showed different profiles. In the cortex, GLT-1a mRNA which appears as the most abundant isoform at a pre-symptomatic stage was strongly decreased during the progression of the disease while GLT-1b mRNA increased to reach a similar level as GLT-1a at end-stage. In the lumbar spinal cord of transgenic rats, both GLT-1a and GLT-1b mRNAs, expressed at the same levels before the symptom onset, were strongly decreased in the ventral horns. While no modification of GLAST was detected, EAAC1 mRNA was highly increased at a pre-symptomatic stage in transgenic animals, explaining a higher activity of glutamate transporters at this age. These results demonstrate that glutamate transporters are differentially expressed in nervous structures of wild-type and transgenic animals although the total GLT-1 activity was constantly decreased during the disease progression. © 2013 Elsevier Ltd. All rights reserved.

M. C. Focant, S. Goursaud, C. Boucherie, A. O. Dumont and E. Hermans (2013) Neuropathology and Applied Neurobiology39, 231-242 PICK1 expression in reactive astrocytes within the spinal cord of amyotrophic lateral sclerosis (ALS) rats Aims: The protein interacting with C kinase 1 (PICK1), a PDZ domain-containing protein mainly expressed in the central nervous system, interacts with the glutamate receptor subunit GluR2, with the glutamate transporter GLT-1b and with the enzyme serine racemase. These three proteins appear as key actors in the glutamate-mediated excitotoxicity associated with amyotrophic lateral sclerosis (ALS), in both patients and animal models of the disease. In this study, we examined the expression of PICK1 in the spinal cord of transgenic rats expressing a mutated form of the human superoxide dismutase 1 (hSOD1 ) during the progression of the disease. Methods: Expression of PICK1 was examined by real-time qPCR at presymptomatic and symptomatic stages as well as at end-stage. The expression of PICK1 in the different cell types of the spinal cord was examined by immunohistochemistry. Results: The overall expression of PICK1 is not modified in cervical and lumbar spinal cord of transgenic (hSOD1 ) rats during the progression of the disease. Nonetheless, immunohistochemical studies of lumbar ventral horns revealed a shift of PICK1 expression from motor neurones in healthy rats to activated astrocytes in end-stage hSOD1 animals. Conclusions: Considering the documented influence of PICK1 expression on d-serine release and glutamate transport in astrocytes, these findings point to a potential implication of PICK1 in the progression of ALS.

Metabotropic glutamate receptors (mGluRs) were previously shown to modulate several essential functions in glial cells, including cell proliferation, glutamate uptake, neurotrophic support, and inflammatory responses. As these receptors are regularly proposed as promising targets for the treatment of a wide range of neurological disorders, we herein examined the reciprocal modulation of glial mGluRs by inflammation. Such regulation of mGluRs was also studied in cultures from an experimental model of amyotrophic lateral sclerosis (ALS). Indeed, ALS is characterized by increased neuroinflammation, and glial cell cultures derived from the animal model (rat expressing hSOD1(G93A)) show enhanced glial reactivity. Within 72 h, the pro-inflammatory cytokines tumor necrosis factor α (TNFα) and interleukin 1β (IL-1β) induced an increase in mGluR3 and a decrease in mGluR5 gene expression. A similar regulation of these receptors was observed in microglia 48 h after an initial 4-h exposure to lipopolysaccharide. In hSOD1(G93A)-derived glial cultures, the gene up-regulation of mGluR3 (but not the gene down-regulation of mGluR5) was found to be enhanced in both astrocytes and microglia. Together, these results indicate that an inflammatory environment triggers an opposite regulation in the gene expression of the two predominant mGluR subtypes found in glial cells, and that these regulations were particularly robust in hSOD1(G93A) glial cultures. As neuroinflammation commonly occurs in several nervous diseases, its influence on mGluR expression should be taken into account when considering these receptors as future drug targets.

Dysregulation of the astroglial glutamate transporters GLAST and GLT-1 has been implicated in several neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) where a loss of GLT-1 protein expression and activity is reported. Furthermore, the two principal C-terminal splice variants of GLT-1 (namely GLT-1a and GLT-1b) show altered expression ratio in animal models of this disease. Considering the putative link between inflammation and excitotoxicity, we have here characterized the influence of TNF-α on glutamate transporters in cerebral cortical astrocyte cultures from wild-type rats and from a rat model of ALS (hSOD1G93A). Contrasting with the down-regulation of GLAST, a 72 h treatment with TNF-α substantially increased the expression of GLT-1a and GLT-1b in both astrocyte cultures. However, as the basal level of GLT-1a appeared considerably lower in hSOD1G93A astrocytes, its up-regulation by TNF-α was insufficient to recapitulate the expression observed in wild-type astrocytes. Also the glutamate uptake activity after TNF-α treatment was lower for hSOD1G93A astrocytes as compared to wild-type astrocytes. In the presence of the protein synthesis inhibitor cycloheximide, TNF-α did not influence GLT-1 isoform expression, suggesting an active role of dynamically regulated protein partners in the adaptation of astrocytes to the inflammatory environment. Confirming the influence of inflammation on the control of glutamate transmission by astrocytes, these results shed light on the regulation of glutamate transporter isoforms in neurodegenerative disorders.

Under hypoxia, cancer cells consume glucose and release lactate at a high rate. Lactate was recently documented to be recaptured by oxygenated cancer cells to fuel the TCA cycle and thereby to support tumor growth. Monocarboxylate transporters (MCT) are the main lactate carriers and therefore represent potential therapeutic targets to limit cancer progression. In this study, we have developed and implemented a stepwise in vitro screening procedure on human cancer cells to identify new potent MCT inhibitors. Various 7-substituted carboxycoumarins and quinolinone derivatives were synthesized and pharmacologically evaluated. Most active compounds were obtained using a palladium-catalyzed Buchwald-Hartwig type coupling reaction, which proved to be a quick and efficient method to obtain aminocarboxycoumarin derivatives. Inhibition of lactate flux revealed that the most active compound 19 (IC 50 11 nM) was three log orders more active than the CHC reference compound. Comparison with warfarin, a conventional anticoagulant coumarin, further showed that compound 19 did not influence the prothrombin time which, together with a good in vitro ADME profile, supports the potential of this new family of compounds to act as anticancer drugs through inhibition of lactate flux. © 2013 Elsevier Ltd. All rights reserved.